The purpose of this study is to confirm no absorption of proton pump inhibitor (PPI), lansoprazole (LPZ), from the oral cavity and bioequivalence between swallowable LPZ fast disintegrating tablet (LFDT) and LPZ capsule (LC).
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Prior to the studies, 119 healthy human volunteers received 30 mg LC to determine the phenotype for LPZ using the serum LPZ sulphone, a metabolite of LPZ, concentration at 4 hr after dosing. 97 subjects were found out to be extensive metabolizers (EM). 72 EMs were used in the following three studies.
Step 1: 12 healthy male EM volunteers were included in a randomized, open, cross-over study to examine the absorption of LPZ from the oral cavity with washout period of at least 1 week between treatments. They kept 30 mg LFDT in their mouth for 2 minutes and the saliva was recovered without swallow (recovery dosing) or they swallowed 30 mg LFDT with 150 mL of water (swallowing dosing). The absorption of LPZ from the oral cavity was examined by comparing the serum LPZ concentration vs. time curves.
Step 2: The bioequivalence of LFDT to LC was examined at two doses, 15 mg and 30 mg, with 24 healthy male EM volunteers for each dose, using a randomized, open, cross-over design. Serum LPZ concentrations were determined up to 24 hr and area under the concentration-time curve (AUC0-24) and maximum serum concentration (Cmax) were determined.
Step 3: 12 healthy male EM volunteers were included in a randomized, open, cross-over study to compare the effect of a single oral dose of LPZ Fast Disintegrating Tablet (30 mg LFDT) administered with 150 mL of water or without water.
Step 1: The ratio of average AUC0-24 of recovery 
